Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is 18.64% higher on its value in year-to-date trading and has touched a low of $13.40 and a high of $25.23 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACAD stock was last observed hovering at around $21.98 in the last trading session, with the day’s loss setting it -0.21%.
Currently trading at $21.77, the stock is 7.97% and 26.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.85 million and changing -0.96% at the moment leaves the stock 28.31% off its SMA200. ACAD registered 44.17% gain for a year compared to 6-month loss of 33.39%. The firm has a 50-day simple moving average (SMA 50) of $17.1998 and a 200-day simple moving average (SMA200) of $16.9665.
The stock witnessed a 43.79% gain in the last 1 month and extending the period to 3 months gives it a 20.41%, and is -1.14% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.32% over the week and 6.08% over the month.
Acadia Pharmaceuticals Inc (ACAD) has around 654 employees, a market worth around $3.64B and $996.28M in sales. Current P/E ratio is 15.85 and Fwd P/E is 25.43. Profit margin for the company is 22.97%. Distance from 52-week low is 62.46% and -13.71% from its 52-week high. The company has generated returns on investments over the last 12 months (28.26%).
with sales reaching $262.89M over the same period.The EPS is expected to shrink by -61.70% this year, but quarterly earnings will post 11.19% year-over-year. Quarterly sales are estimated to grow 8.65% in year-over-year returns.
429.0 institutions hold shares in Acadia Pharmaceuticals Inc (ACAD), with institutional investors hold 106.30% of the company’s shares. The shares outstanding are 167.12M, and float is at 166.06M with Short Float at 9.18%. Institutions hold 105.56% of the Float.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 42.88 million shares valued at $$696.77 million. The investor’s holdings represent 25.9001 of the ACAD Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.71 million shares valued at $$222.82 million to account for 8.2827 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 13.71 million shares representing 8.2799 and valued at over $$222.75 million, while BLACKROCK INC. holds 7.2861 of the shares totaling 12.06 million with a market value of $$196.01 million.
Acadia Pharmaceuticals Inc (ACAD) Insider Activity
Acadia Pharmaceuticals Inc disclosed in a document filed with the SEC on May 16 ’25 that Kihara James (PRINCIPAL ACCOUNTING OFFICER) sold a total of 4,000 shares of the company’s common stock. The trade occurred on May 16 ’25 and was made at $22.50 per share for $90000.0. Following the transaction, the insider now directly holds 20395.0 shares of the ACAD stock.
Still, SEC filings show that on May 16 ’25, Schneyer Mark C. (EVP, CHIEF FINANCIAL OFFICER) disposed off 2,000 shares at an average price of $25.00 for $50000.0. The insider now directly holds 62,130 shares of Acadia Pharmaceuticals Inc (ACAD).
